Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates
To evaluate the immunogenicity and efficacy of an inactivated dual-subtype feline immunodeficiency virus (FIV) vaccine. Specific-pathogen-free cats were immunized with dual-subtype (subtype A FIV(Pet) and subtype D FIV(Shi)) vaccine and challenged with either in vivo- or in vitro-derived FIV inocula...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2001-07, Vol.15 (10), p.1225-1237 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1237 |
|---|---|
| container_issue | 10 |
| container_start_page | 1225 |
| container_title | AIDS (London) |
| container_volume | 15 |
| creator | RUIYU PU COLEMAN, James OMORI, Mayuko ARAI, Maki HOHDATSU, Tsutomu CHENGJIN HUANG TANABE, Taishi YAMAMOTO, Janet K |
| description | To evaluate the immunogenicity and efficacy of an inactivated dual-subtype feline immunodeficiency virus (FIV) vaccine.
Specific-pathogen-free cats were immunized with dual-subtype (subtype A FIV(Pet) and subtype D FIV(Shi)) vaccine and challenged with either in vivo- or in vitro-derived FIV inocula.
Dual-subtype vaccinated, single-subtype vaccinated, and placebo-immunized cats were challenged within vivo-derived heterologous subtype B FIV(Bang) [10--100 50% cat infectious doses (CID(50))], in vivo-derived homologous FIV(Shi)(50 CID(50)), and in vitro- and in vivo-derived homologous FIV(Pet)(20--50 CID(50)). Dual-subtype vaccine immunogenicity and efficacy were evaluated and compared to single-subtype strain vaccines. FIV infection was determined using virus isolation and proviral PCR of peripheral blood mononuclear cells and lymphoid tissues.
Four out of five dual-subtype vaccinated cats were protected against low-dose FIV(Bang) (10 CID(50)) and subsequently against in vivo-derived FIV(Pet) (50 CID(50)) challenge, whereas all placebo-immunized cats became infected. Furthermore, dual-subtype vaccine protected two out of five cats against high-dose FIV(Bang) challenge (100 CID(50)) which infected seven out of eight single-subtype vaccinated cats. All dual-subtype vaccinated cats were protected against in vivo-derived FIV(Pet), but only one out of five single-subtype vaccinated cats were protected against in vivo-derived FIV(Pet). Dual-subtype vaccination induced broad-spectrum virus-neutralizing antibodies and FIV-specific interferon-gamma responses along with elevated FIV-specific perforin mRNA levels, suggesting an increase in cytotoxic cell activities.
Dual-subtype vaccinated cats developed broad-spectrum humoral and cellular immunity which protected cats against in vivo-derived inocula of homologous and heterologous FIV subtypes. Thus, multi-subtype antigen vaccines may be an effective strategy against AIDS viruses. |
| doi_str_mv | 10.1097/00002030-200107060-00004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70967698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70967698</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-eb911d869b3f3ad6fbf1580abeab4ba03901697d0facf28a4f193dd7f05f62f53</originalsourceid><addsrcrecordid>eNqFkU1P3DAQhq2qqCy0f6HyAfUWGMeJP47V0gUkpF4K12js2GyqJN7GzqL99_XC0u6NOcxIr5750ksIZXDJQMsryFECh6IEYCBBQLGXqg9kwSrJi7qW7CNZQCl0obmEU3IW4-9M1KDUJ3LKWFUKEHJBttcz9kWcTdptHF3dPdItWtuNjm6mkJxNkVrMCZ-wG2Oi3Ui33TbQ-IzTEGnw1IS0puswhD48hTmTY0vXLrnpTTge3sXQY3LxMznx2Ef35VDPycPqx6_lbXH_8-Zu-f2-sJWSqXBGM9YqoQ33HFvhjWe1AjQOTWUQuAYmtGzBo_WlwsozzdtWeqi9KH3Nz8m317n5mz-zi6kZumhd3-Po8m2NBC2k0OpdkEnNKgE8g-oVtFOIcXK-2UzdgNOuYdDszWnezGn-mfMiVbn162HHbAbX_m88uJGBiwOA0WLvJxxtF48W6FJpzv8C9oiY3w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17914603</pqid></control><display><type>article</type><title>Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>RUIYU PU ; COLEMAN, James ; OMORI, Mayuko ; ARAI, Maki ; HOHDATSU, Tsutomu ; CHENGJIN HUANG ; TANABE, Taishi ; YAMAMOTO, Janet K</creator><creatorcontrib>RUIYU PU ; COLEMAN, James ; OMORI, Mayuko ; ARAI, Maki ; HOHDATSU, Tsutomu ; CHENGJIN HUANG ; TANABE, Taishi ; YAMAMOTO, Janet K</creatorcontrib><description>To evaluate the immunogenicity and efficacy of an inactivated dual-subtype feline immunodeficiency virus (FIV) vaccine.
Specific-pathogen-free cats were immunized with dual-subtype (subtype A FIV(Pet) and subtype D FIV(Shi)) vaccine and challenged with either in vivo- or in vitro-derived FIV inocula.
Dual-subtype vaccinated, single-subtype vaccinated, and placebo-immunized cats were challenged within vivo-derived heterologous subtype B FIV(Bang) [10--100 50% cat infectious doses (CID(50))], in vivo-derived homologous FIV(Shi)(50 CID(50)), and in vitro- and in vivo-derived homologous FIV(Pet)(20--50 CID(50)). Dual-subtype vaccine immunogenicity and efficacy were evaluated and compared to single-subtype strain vaccines. FIV infection was determined using virus isolation and proviral PCR of peripheral blood mononuclear cells and lymphoid tissues.
Four out of five dual-subtype vaccinated cats were protected against low-dose FIV(Bang) (10 CID(50)) and subsequently against in vivo-derived FIV(Pet) (50 CID(50)) challenge, whereas all placebo-immunized cats became infected. Furthermore, dual-subtype vaccine protected two out of five cats against high-dose FIV(Bang) challenge (100 CID(50)) which infected seven out of eight single-subtype vaccinated cats. All dual-subtype vaccinated cats were protected against in vivo-derived FIV(Pet), but only one out of five single-subtype vaccinated cats were protected against in vivo-derived FIV(Pet). Dual-subtype vaccination induced broad-spectrum virus-neutralizing antibodies and FIV-specific interferon-gamma responses along with elevated FIV-specific perforin mRNA levels, suggesting an increase in cytotoxic cell activities.
Dual-subtype vaccinated cats developed broad-spectrum humoral and cellular immunity which protected cats against in vivo-derived inocula of homologous and heterologous FIV subtypes. Thus, multi-subtype antigen vaccines may be an effective strategy against AIDS viruses.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/00002030-200107060-00004</identifier><identifier>PMID: 11426067</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>AIDS/HIV ; Animals ; Base Sequence ; Biological and medical sciences ; Cats ; DNA Primers ; Experimental viral diseases and models ; Feline Acquired Immunodeficiency Syndrome - immunology ; Feline Acquired Immunodeficiency Syndrome - prevention & control ; feline immunodeficiency virus ; g-Interferon ; Immunity, Cellular ; Immunodeficiency Virus, Feline - immunology ; Infectious diseases ; Interferon-gamma - biosynthesis ; Medical sciences ; Neutralization Tests ; Placebos ; Polymerase Chain Reaction ; Viral diseases ; Viral Vaccines - immunology</subject><ispartof>AIDS (London), 2001-07, Vol.15 (10), p.1225-1237</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-eb911d869b3f3ad6fbf1580abeab4ba03901697d0facf28a4f193dd7f05f62f53</citedby><cites>FETCH-LOGICAL-c487t-eb911d869b3f3ad6fbf1580abeab4ba03901697d0facf28a4f193dd7f05f62f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1092893$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11426067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RUIYU PU</creatorcontrib><creatorcontrib>COLEMAN, James</creatorcontrib><creatorcontrib>OMORI, Mayuko</creatorcontrib><creatorcontrib>ARAI, Maki</creatorcontrib><creatorcontrib>HOHDATSU, Tsutomu</creatorcontrib><creatorcontrib>CHENGJIN HUANG</creatorcontrib><creatorcontrib>TANABE, Taishi</creatorcontrib><creatorcontrib>YAMAMOTO, Janet K</creatorcontrib><title>Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>To evaluate the immunogenicity and efficacy of an inactivated dual-subtype feline immunodeficiency virus (FIV) vaccine.
Specific-pathogen-free cats were immunized with dual-subtype (subtype A FIV(Pet) and subtype D FIV(Shi)) vaccine and challenged with either in vivo- or in vitro-derived FIV inocula.
Dual-subtype vaccinated, single-subtype vaccinated, and placebo-immunized cats were challenged within vivo-derived heterologous subtype B FIV(Bang) [10--100 50% cat infectious doses (CID(50))], in vivo-derived homologous FIV(Shi)(50 CID(50)), and in vitro- and in vivo-derived homologous FIV(Pet)(20--50 CID(50)). Dual-subtype vaccine immunogenicity and efficacy were evaluated and compared to single-subtype strain vaccines. FIV infection was determined using virus isolation and proviral PCR of peripheral blood mononuclear cells and lymphoid tissues.
Four out of five dual-subtype vaccinated cats were protected against low-dose FIV(Bang) (10 CID(50)) and subsequently against in vivo-derived FIV(Pet) (50 CID(50)) challenge, whereas all placebo-immunized cats became infected. Furthermore, dual-subtype vaccine protected two out of five cats against high-dose FIV(Bang) challenge (100 CID(50)) which infected seven out of eight single-subtype vaccinated cats. All dual-subtype vaccinated cats were protected against in vivo-derived FIV(Pet), but only one out of five single-subtype vaccinated cats were protected against in vivo-derived FIV(Pet). Dual-subtype vaccination induced broad-spectrum virus-neutralizing antibodies and FIV-specific interferon-gamma responses along with elevated FIV-specific perforin mRNA levels, suggesting an increase in cytotoxic cell activities.
Dual-subtype vaccinated cats developed broad-spectrum humoral and cellular immunity which protected cats against in vivo-derived inocula of homologous and heterologous FIV subtypes. Thus, multi-subtype antigen vaccines may be an effective strategy against AIDS viruses.</description><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>Cats</subject><subject>DNA Primers</subject><subject>Experimental viral diseases and models</subject><subject>Feline Acquired Immunodeficiency Syndrome - immunology</subject><subject>Feline Acquired Immunodeficiency Syndrome - prevention & control</subject><subject>feline immunodeficiency virus</subject><subject>g-Interferon</subject><subject>Immunity, Cellular</subject><subject>Immunodeficiency Virus, Feline - immunology</subject><subject>Infectious diseases</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Medical sciences</subject><subject>Neutralization Tests</subject><subject>Placebos</subject><subject>Polymerase Chain Reaction</subject><subject>Viral diseases</subject><subject>Viral Vaccines - immunology</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1P3DAQhq2qqCy0f6HyAfUWGMeJP47V0gUkpF4K12js2GyqJN7GzqL99_XC0u6NOcxIr5750ksIZXDJQMsryFECh6IEYCBBQLGXqg9kwSrJi7qW7CNZQCl0obmEU3IW4-9M1KDUJ3LKWFUKEHJBttcz9kWcTdptHF3dPdItWtuNjm6mkJxNkVrMCZ-wG2Oi3Ui33TbQ-IzTEGnw1IS0puswhD48hTmTY0vXLrnpTTge3sXQY3LxMznx2Ef35VDPycPqx6_lbXH_8-Zu-f2-sJWSqXBGM9YqoQ33HFvhjWe1AjQOTWUQuAYmtGzBo_WlwsozzdtWeqi9KH3Nz8m317n5mz-zi6kZumhd3-Po8m2NBC2k0OpdkEnNKgE8g-oVtFOIcXK-2UzdgNOuYdDszWnezGn-mfMiVbn162HHbAbX_m88uJGBiwOA0WLvJxxtF48W6FJpzv8C9oiY3w</recordid><startdate>20010706</startdate><enddate>20010706</enddate><creator>RUIYU PU</creator><creator>COLEMAN, James</creator><creator>OMORI, Mayuko</creator><creator>ARAI, Maki</creator><creator>HOHDATSU, Tsutomu</creator><creator>CHENGJIN HUANG</creator><creator>TANABE, Taishi</creator><creator>YAMAMOTO, Janet K</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20010706</creationdate><title>Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates</title><author>RUIYU PU ; COLEMAN, James ; OMORI, Mayuko ; ARAI, Maki ; HOHDATSU, Tsutomu ; CHENGJIN HUANG ; TANABE, Taishi ; YAMAMOTO, Janet K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-eb911d869b3f3ad6fbf1580abeab4ba03901697d0facf28a4f193dd7f05f62f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>Cats</topic><topic>DNA Primers</topic><topic>Experimental viral diseases and models</topic><topic>Feline Acquired Immunodeficiency Syndrome - immunology</topic><topic>Feline Acquired Immunodeficiency Syndrome - prevention & control</topic><topic>feline immunodeficiency virus</topic><topic>g-Interferon</topic><topic>Immunity, Cellular</topic><topic>Immunodeficiency Virus, Feline - immunology</topic><topic>Infectious diseases</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Medical sciences</topic><topic>Neutralization Tests</topic><topic>Placebos</topic><topic>Polymerase Chain Reaction</topic><topic>Viral diseases</topic><topic>Viral Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RUIYU PU</creatorcontrib><creatorcontrib>COLEMAN, James</creatorcontrib><creatorcontrib>OMORI, Mayuko</creatorcontrib><creatorcontrib>ARAI, Maki</creatorcontrib><creatorcontrib>HOHDATSU, Tsutomu</creatorcontrib><creatorcontrib>CHENGJIN HUANG</creatorcontrib><creatorcontrib>TANABE, Taishi</creatorcontrib><creatorcontrib>YAMAMOTO, Janet K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RUIYU PU</au><au>COLEMAN, James</au><au>OMORI, Mayuko</au><au>ARAI, Maki</au><au>HOHDATSU, Tsutomu</au><au>CHENGJIN HUANG</au><au>TANABE, Taishi</au><au>YAMAMOTO, Janet K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2001-07-06</date><risdate>2001</risdate><volume>15</volume><issue>10</issue><spage>1225</spage><epage>1237</epage><pages>1225-1237</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>To evaluate the immunogenicity and efficacy of an inactivated dual-subtype feline immunodeficiency virus (FIV) vaccine.
Specific-pathogen-free cats were immunized with dual-subtype (subtype A FIV(Pet) and subtype D FIV(Shi)) vaccine and challenged with either in vivo- or in vitro-derived FIV inocula.
Dual-subtype vaccinated, single-subtype vaccinated, and placebo-immunized cats were challenged within vivo-derived heterologous subtype B FIV(Bang) [10--100 50% cat infectious doses (CID(50))], in vivo-derived homologous FIV(Shi)(50 CID(50)), and in vitro- and in vivo-derived homologous FIV(Pet)(20--50 CID(50)). Dual-subtype vaccine immunogenicity and efficacy were evaluated and compared to single-subtype strain vaccines. FIV infection was determined using virus isolation and proviral PCR of peripheral blood mononuclear cells and lymphoid tissues.
Four out of five dual-subtype vaccinated cats were protected against low-dose FIV(Bang) (10 CID(50)) and subsequently against in vivo-derived FIV(Pet) (50 CID(50)) challenge, whereas all placebo-immunized cats became infected. Furthermore, dual-subtype vaccine protected two out of five cats against high-dose FIV(Bang) challenge (100 CID(50)) which infected seven out of eight single-subtype vaccinated cats. All dual-subtype vaccinated cats were protected against in vivo-derived FIV(Pet), but only one out of five single-subtype vaccinated cats were protected against in vivo-derived FIV(Pet). Dual-subtype vaccination induced broad-spectrum virus-neutralizing antibodies and FIV-specific interferon-gamma responses along with elevated FIV-specific perforin mRNA levels, suggesting an increase in cytotoxic cell activities.
Dual-subtype vaccinated cats developed broad-spectrum humoral and cellular immunity which protected cats against in vivo-derived inocula of homologous and heterologous FIV subtypes. Thus, multi-subtype antigen vaccines may be an effective strategy against AIDS viruses.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>11426067</pmid><doi>10.1097/00002030-200107060-00004</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2001-07, Vol.15 (10), p.1225-1237 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70967698 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | AIDS/HIV Animals Base Sequence Biological and medical sciences Cats DNA Primers Experimental viral diseases and models Feline Acquired Immunodeficiency Syndrome - immunology Feline Acquired Immunodeficiency Syndrome - prevention & control feline immunodeficiency virus g-Interferon Immunity, Cellular Immunodeficiency Virus, Feline - immunology Infectious diseases Interferon-gamma - biosynthesis Medical sciences Neutralization Tests Placebos Polymerase Chain Reaction Viral diseases Viral Vaccines - immunology |
| title | Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T00%3A42%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual-subtype%20FIV%20vaccine%20protects%20cats%20against%20in%20vivo%20swarms%20of%20both%20homologous%20and%20heterologous%20subtype%20FIV%20isolates&rft.jtitle=AIDS%20(London)&rft.au=RUIYU%20PU&rft.date=2001-07-06&rft.volume=15&rft.issue=10&rft.spage=1225&rft.epage=1237&rft.pages=1225-1237&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/00002030-200107060-00004&rft_dat=%3Cproquest_cross%3E70967698%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17914603&rft_id=info:pmid/11426067&rfr_iscdi=true |